Compare Xylem, Inc. (XYL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Xylem, Inc. vs Zoetis Inc — how do they compare? Xylem, Inc. trades at $107.96 (market cap $25.13B), while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| XYL | ZTS | |
|---|---|---|
Market Cap | $25.13B | $30.29B |
Sector | Industrials | Health |
52-Week High | $152.95 | $150.61 |
52-Week Low | $105.69 | $71.91 |
Enterprise Value | $26.91B | $37.86B |
Dividend Yield | 1.6% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Xylem (XYL) trades at $108.81, up 2.95% in the last session, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.46 exceeding expectations. Revenue growth has been steady, rising from $5.5B in 2022 to $9.0B in 2025, while net income margins improved to 10.59%. Recent corporate actions include a dividend declaration and strategic acquisitions to bolster its industrial presence.
The outlook for XYL is positive based on earnings momentum and strategic initiatives, though technical indicators suggest near-term caution. Upside potential is supported by a consensus price target of $152.29, implying significant appreciation. Risks include execution of recent acquisitions and macroeconomic pressures on industrial demand. The stock presents a compelling opportunity for long-term investors focused on water infrastructure growth.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
